Supplementary Figure 9 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Kaushik Varadarajan; Christian X. Cruz Pico; Kurt W. Evans; Maria Gabriela Raso; Yasmeen Q. Rizvi; Xiaofeng Zheng; Dhruv Chachad; Timothy P. DiPeri; Bailiang Wang; Stephen M. Scott; Ming Zhao; Argun Akçakanat; Antje M. Wengner; Timothy A. Yap; Funda Meric‐Bernstam

doi:10.1158/1535-7163.30028651

September 2, 2025Open Access

Supplementary Figure 9 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

View Full Paper

Ask AI

Bookmark

Share

Key Points

Enhanced efficacy is observed with elimusertib in tumors exhibiting dna damage response alterations, and potential benefits of combination therapy are suggested.
The analysis involved various pharmacodynamic experiments showcasing results from ihc and rppa methods, focusing on tumor response.
This observational assessment delivers insights into elimusertib's role as an atr kinase inhibitor, especially in the context of genomic alterations.
Findings emphasize the significance of understanding dna damage response pathways, pointing to further development for targeted therapies.

Implication

Observational analysis shows enhanced efficacy of atr kinase inhibitor elimusertib in tumors with genomic alterations, indicating potential for improved cancer treatment.

Abstract

Supplementary Figure 9: Additional IHC and RPPA results from pharmacodynamic experiments.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Varadarajan et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd029bb https://doi.org/10.1158/1535-7163.30028651

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure 9 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure 9 from Efficacy of ATR Kinase Inhibitor Elimusertib Monotherapy or Combination in Tumors with DNA Damage Response Pathway and Other Genomic Alterations

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading